You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 8,119,127

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,119,127

Title:	Cytokine antagonists for neurological and neuropsychiatric disorders
Abstract:	Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additionally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer\'s Disease and Parkinson\'s Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathetic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawal, post-partum depression, and schizoaffective illness.
Inventor(s):	Tobinick; Edward L (Los Angeles, CA)
Assignee:	Tact IP, LLC (N/A)
Application Number:	11/262,528
Patent Claims:	1. A method for delivering etanercept to a human, comprising: administering etanercept to said human by perispinal injection without direct intrathecal or epidural injection. 2. A method for delivering etanercept to the cerebrospinal fluid of a human, comprising: administering etanercept to said human by perispinal injection without direct intrathecal or epidural injection.

Details for Patent 8,119,127

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL	etanercept	Injection	103795	03/05/2020	⤷ Try a Trial	2019-02-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.